Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of SFP in Hemodialysis Patients
NCT01503021Phase 3Completed
- Sponsor
- Rockwell Medical
- Start
- Nov 2011
- Primary completion
- Jan 2014
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ferric pyrophosphate in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Rockwell Medical. Primary endpoints: Incidence of Treatment-emergent Adverse Events at 53 weeks, Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension at 53 weeks and 1 more. Started Nov 2011; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01503021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503021.